

September 2, 2015



Actinium to Present at Rodman & Renshaw 17th Annual Global Investment Conference

NEW YORK, NY -- (Marketwired) -- 09/02/15 -- Actinium Pharmaceuticals, Inc. (NYSE MKT: ATNM) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that it will be presenting at the Rodman & Renshaw 17th Annual Global Investment Conference, held September 8-10, 2015 at the St. Regis Hotel, New York City.

Event: Rodman & Renshaw 17th Annual Global Investment Conference

Location: St. Regis Hotel, NYC

Date: September 10, 2015

Webcast: <http://wsw.com/webcast/rrshq25/atnm>

Actinium's Executive Chairman, Sandesh Seth, will deliver the Company's corporate presentation and discuss its recent business highlights. In addition to the presentation, Mr. Seth will also be available for one-on-one meetings.

Members of the investment community who are interested in meeting with Actinium's management should please contact Robert Haag at atnm@irthcommunications.com or 1-866-976-4784. Please visit this [link](#) to schedule a one-on-one scheduling directly.

About Rodman & Renshaw Conferences, LLC

The Rodman & Renshaw Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, is held on September 8 through September 10, 2015 at the St. Regis Hotel in New York. More than 200 public & private companies from around the world are expected to present to an audience of over 2,000 attendees. The event will feature tracks devoted to Biotechnology/Healthcare, Metals & Mining, Technology, Cleantech and Growth. The Conference will include corporate presentations and Q&A sessions, investor one-on-one meetings and daily networking opportunities.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. is a New York, NY based biopharmaceutical company that develops innovative alpha particle immunotherapeutics based on its proprietary platform for the therapeutic utilization of alpha particle emitting actinium-225 and bismuth-213 radiopharmaceuticals in association with monoclonal antibodies.

Forward-Looking Statements for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current

expectations and involve risks and uncertainties, which may cause actual results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Investor and Media Relations:

Robert Haag
Managing Partner
IRTH Communications
atnm@irthcommunications.com
1-866-976-4784

Contact:
David Gould, MD
SVP, Finance and Corporate Development
Actinium Pharmaceuticals, Inc.
dgould@actiniumpharma.com

Source: Actinium Pharmaceuticals